Abstract Objective The serum ischemia modified albumin (IMA), biglycan, and decorin levels of pregnant women who were hospitalized for threatened preterm labor were measured. Methods Fifty-one consecutive pregnant women with a single pregnancy between the 24th and 36th weeks with a diagnosis of threatened preterm labor were included in the present prospective cohort study. Results As a result of multivariate logistic regression analysis for predicting preterm delivery within 24 hours, 48 hours, 7 days, 14 days, ≤ 35 gestational weeks, and ≤ 37 gestational weeks after admission, area under the curve (AUC) (95% confidence interval [CI[) values were 0.95 (0.89–1.00), 0.93 (0.86–0.99), 0.91 (0.83–0.98), 0.92 (0.85–0.99), 0.82 (0.69–0.96), and 0.89 (0.80–0.98), respectively. In the present study, IMA and biglycan levels were found to be higher and decorin levels lower in women admitted to the hospital with threatened preterm labor and who gave preterm birth within 48 hours compared with those who gave birth after 48 hours. Conclusion In pregnant women admitted to the hospital with threatened preterm labor, the prediction preterm delivery of the combined model created by adding IMA, decorin, and biglycan in addition to the TVS CL measurement was higher than the TVS CL measurement alone. Clinical trial registration The present trial was registered at ClinicalTrials.gov, number NCT04451928. , (IMA) measured Fiftyone Fifty one th study 2 4 days 1 3 admission AUC (AUC 95% 95 (95 CI [CI[ 095 0 0.9 0.89–1.00, 089100 0.89–1.00 89 00 (0.89–1.00) 093 93 0.86–0.99, 086099 0.86–0.99 86 99 (0.86–0.99) 091 91 0.83–0.98, 083098 0.83–0.98 83 98 (0.83–0.98) 092 92 0.85–0.99, 085099 0.85–0.99 85 (0.85–0.99) 082 82 0.8 0.69–0.96, 069096 0.69–0.96 69 96 (0.69–0.96) 089 0.80–0.98, 080098 0.80–0.98 80 (0.80–0.98) respectively alone ClinicalTrialsgov ClinicalTrials gov ClinicalTrials.gov NCT04451928 NCT (IMA 9 (9 [CI 09 0. 08910 0.89–1.0 8 (0.89–1.00 08609 0.86–0.9 (0.86–0.99 08309 0.83–0.9 (0.83–0.98 08509 0.85–0.9 (0.85–0.99 08 06909 0.69–0.9 6 (0.69–0.96 08009 0.80–0.9 (0.80–0.98 NCT0445192 ( 0891 0.89–1. (0.89–1.0 0860 0.86–0. (0.86–0.9 0830 0.83–0. (0.83–0.9 0850 0.85–0. (0.85–0.9 0690 0.69–0. (0.69–0.9 0800 0.80–0. (0.80–0.9 NCT044519 0.89–1 (0.89–1. 086 0.86–0 (0.86–0. 083 0.83–0 (0.83–0. 085 0.85–0 (0.85–0. 069 0.69–0 (0.69–0. 080 0.80–0 (0.80–0. NCT04451 0.89– (0.89–1 0.86– (0.86–0 0.83– (0.83–0 0.85– (0.85–0 06 0.69– (0.69–0 0.80– (0.80–0 NCT0445 (0.89– 0.86 (0.86– 0.83 (0.83– 0.85 (0.85– 0.69 (0.69– 0.80 (0.80– NCT044 (0.89 (0.86 (0.83 (0.85 0.6 (0.69 (0.80 NCT04 (0.8 (0.6 NCT0 (0. (0
Resumo Objetivo Medir os níveis séricos de albumina modificada por isquemia (IMA), biglicano e decorina de gestantes hospitalizadas por ameaça de parto prematuro. Métodos Cinquenta e uma mulheres grávidas consecutivas com uma única gravidez entre a 24ᵃ e a 36ᵃ semanas com diagnóstico de ameaça de trabalho de parto prematuro foram incluídas no presente estudo de corte prospectivo. Resultados Como resultado da análise de regressão logística multivariada para prever parto prematuro dentro de 24 horas, 48 horas, 7 dias, 14 dias, ≤ 35 semanas gestacionais e ≤ 37 semanas gestacionais após a admissão, área sob a curva (AUC) (95% de confiança os valores de intervalo [CI[) foram 0,95 (0,89–1,00), 0,93 (0,86–0,99), 0,91 (0,83–0,98), 0,92 (0,85–0,99), 0,82 (0,69–0,96) e 0,89 (0,80–0,98), respectivamente. No presente estudo, os níveis de IMA e biglican foram maiores e os níveis de decorin menores em mulheres admitidas no hospital com ameaça de trabalho de parto prematuro e que tiveram parto prematuro em 48 horas em comparação com aquelas que deram à luz após 48 horas. Conclusão Em gestantes admitidas no hospital com ameaça de trabalho de parto prematuro, a predição de parto prematuro do modelo combinado criado pela adição de IMA, decorin e biglican, além da medição do TVS CL, foi maior do que a medição do TVS CL isoladamente. Registro do ensaio clínico O presente ensaio foi registrado em ClinicalTrials.gov, número NCT04451928. , (IMA) ᵃ prospectivo 2 4 dias 1 3 admissão AUC (AUC 95% 95 (95 CI [CI[ 095 0 0,9 0,89–1,00, 089100 0,89–1,00 89 00 (0,89–1,00) 093 93 0,86–0,99, 086099 0,86–0,99 86 99 (0,86–0,99) 091 91 0,83–0,98, 083098 0,83–0,98 83 98 (0,83–0,98) 092 92 0,85–0,99, 085099 0,85–0,99 85 (0,85–0,99) 082 82 0,8 0,69–0,96 069096 69 96 (0,69–0,96 089 0,80–0,98, 080098 0,80–0,98 80 (0,80–0,98) respectivamente isoladamente ClinicalTrialsgov ClinicalTrials gov ClinicalTrials.gov NCT04451928 NCT (IMA 9 (9 [CI 09 0, 08910 0,89–1,0 8 (0,89–1,00 08609 0,86–0,9 (0,86–0,99 08309 0,83–0,9 (0,83–0,98 08509 0,85–0,9 (0,85–0,99 08 0,69–0,9 06909 6 (0,69–0,9 08009 0,80–0,9 (0,80–0,98 NCT0445192 ( 0891 0,89–1, (0,89–1,0 0860 0,86–0, (0,86–0,9 0830 0,83–0, (0,83–0,9 0850 0,85–0, (0,85–0,9 0,69–0, 0690 (0,69–0, 0800 0,80–0, (0,80–0,9 NCT044519 0,89–1 (0,89–1, 086 0,86–0 (0,86–0, 083 0,83–0 (0,83–0, 085 0,85–0 (0,85–0, 0,69–0 069 (0,69–0 080 0,80–0 (0,80–0, NCT04451 0,89– (0,89–1 0,86– (0,86–0 0,83– (0,83–0 0,85– (0,85–0 0,69– 06 (0,69– 0,80– (0,80–0 NCT0445 (0,89– 0,86 (0,86– 0,83 (0,83– 0,85 (0,85– 0,69 (0,69 0,80 (0,80– NCT044 (0,89 (0,86 (0,83 (0,85 0,6 (0,6 (0,80 NCT04 (0,8 (0, NCT0 (0